VERV 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
VERV 近期報酬表現
-6.27%
Verve therapeutics inc
4.57%
同產業平均
0.12%
S&P500
與 VERV 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BEAM | Beam therapeutics inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
NTLA | Intellia therapeutics inc | 5 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
CLLS | Cellectis sa - adr | 3 分 | 4 分 | 2 分 | 1 分 | 1 分 | |
EDIT | Editas medicine inc | 2 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
NUVL | Nuvalent inc | - | 3 分 | 4 分 | 3 分 | 1 分 |
- BEAM Beam therapeutics inc價值 3 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
VERV 公司資訊
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company's lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.